ADOT "GENERAL OVERVIEW INFORMATION" (Updated 6-23-98)... by Brad
PLEASE NOTE: This may take a while to read, but I find it to be some of the Most Amazing and Verifiable information I have seen. This is truly exciting to me!
(This information has been compiled by me, an independent investor, and is presented to be as accurate as possible according to what information I have been able to obtain from public and private sources. This should NOT be assumed exact, but can be considered a starting point for research purposes.)
**********************************************************
- COMPANY "SNAPSHOT" -
Advance Optics Electronics - ADOT (OTC:BB)
Recent Price: $0.22
52 Week Range: $0.15 - $1.625
EPS: FY98 (Projected) $.21 to $.23
Outstanding Shares: 12 million
Float: 6 million
Profit Margin: 40%
SEC Filing: July 15, 1998
Business Type:
- Electronic Flat-Panel Advertising Billboards using patented state-of-the-art technology.
- 27% Ownership in Biomoda, Inc, a bio-tech company that has developed a successful cancer detection method that detects cancer 6 years earlier than any other method in use.
(Please read the information below about Biomoda very carefully. Biomoda has verifiable data and could be National Headline News in the coming months.)
******************************************************
Ticker Symbol: ADOT (OTC:BB)
COMPANY:
Advanced Optics Electronics, Inc
5601 Holly NE
Albuquerque, NM 87113
Phone: 505-797-7878
Fax:: 505-858-1871
CEO: Leslie Robins
PATENTED TECHNOLOGY Unites ELECTRONICS with CANCER RESEARCH.
WEB SITE for ADOT: adot.org
WEB SITE for BIOMODA: biomoda.com
Biomoda Phone: 505-898-1446
Business & Technology Contact:
Mr. Ari Ma'ayan (e-mail: 2coaches@internetMCI.com)
Medical & Scientific Contact:
Dr. Jeff Garwin (e-mail: info@biomoda.com)
RECENT PRESS RELEASES:
biz.yahoo.com
SEC STATUS:
ADOT is filing to be a fully reporting company with the SEC by July 15, 1998. However, ADOT already does provide Audited Financial Statements on their web site.
adot.org
********************************************************
- SHARE INFORMATION -
TOTAL SHARES AUTHORIZED: 25 million
TOTAL SHARES OUTSTANDING: 12,050,280 (from 3-31-98 Fin Stmt)
SHARES IN THE FLOAT: Apx 6 million
********************************************************
EARNINGS:
1996 EPS (Actual): (0.14)
1997 EPS (Actual): (0.01) - Company had estimated (0.02) but beat the estimate.
1998 EPS (Estimate): 0.21 to 0.23 (not including Biomoda)
1999 EPS (Estimate): 0.85 to 0.95 (not including Biomoda)
Click Here for 1996, 1997, 1998 Financial Statements
adot.org
REVENUE ESTIMATES:
1998: $4.4 Million from Flat Panel Displays (Not including Biomoda*)
1999: $12.0 Million from Flat Panel Displays (Not including Biomoda*)
*Estimates from BIOMODA are (conservatively) $9 Million in revenue in the third year of commercial administration and $70 Million or more in the fifth year.
Profit margins from BIOMODA are expected to be very, very large!
********************************************************
GENERAL BUSINESS INFORMATION:
ADOT's unique profit potential can be derived from 2 compatible sources...
Profits from Flat Panel Displays and
Profits from BIOMODA Early Cancer Detection and Treatment.
Patented Technology is the link between the Flat Panel Displays and the BIOMODA Early Cancer Detection and Treatment.
Here is a post that references the Patents involved...
Message 4341152
1)
FLAT PANEL DISPLAYS:
Advanced Optics Electronics, Inc (ADOT) is primarily an electro-optic technology company that designs and produces large scale (14' x 42') flat panel displays for the outdoor advertising industry using a patented technology (Patent #5,198,920). The displays will create billboards that more closely resemble large television screens.
ADOT's displays provide crisp images with superior speed and image quality. The Company's turnkey package can create and control billboard graphics from a remote terminal via satellite thus enabling advertisers to sell billboard ad time in blocks similar to TV and radio.
In addition to regular ads, advertisers can also tailor messages for short-term markets such as morning drive-time commuters, up-coming events, etc.
These billboards are designed for new installations and conversions of existing units in the $2.3 Billion outdoor advertising industry. The industry is growing rapidly. Demand is exploding and advertising rates are steadily increasing.
Billboards are highly cost-effective and are usually priced 80% less than TV, 70% less than print media, and 50% less than radio.
The first contract is for $1.7 Million. Delivery was originally set for Jan 98. However, the Buyer has requested modifications and delivery is now projected for later this Summer.
Here is the Patent Information from the Offering Circular from ADOT:
(Remember, ADOT is the successor to PLZTECH which is the assignee to this patent.)
PATENT #5,198,920 : Transverse pixel format electro-optic spatial light modulator
patents.ibm.com
For a More Detailed look at ADOT, please review these posts by JOHN WHITE...
Part 1 of 10 - Message 4238809
Part 2 of 10 - Message 4301954
Part 3 of 10 - Message 4398133
Part 4 of 10 - Message 4489103
Part 5 of 10 - Message 4580756
Part 6 of 10 - Message 4661004
Part 7 of 10 - Message 4755559
Part 8 of 10 - techstocks.com
Part 9 of 10 - Message 4949067
Part 10 of 10 - Coming Later
2)
BIOMODA EARLY CANCER DETECTION & TREATMENT:
(ADOT owns 27% of BIOMODA, INC.)
- - - - - - - - - - - - - - - - - - - -
Background -
BIOMODA Inc. is a bio tech company (not publicly traded) that holds a world-wide exclusive license in perpetuity from the University of California to a NEW patented molecular marker/binder technology for the very early detection of lung cancer AND an integrated treatment for lung cancer. Early detection is as much as 6 years earlier than
other methods used.
Biomoda Patent Info:
Method using 5,10,15,20-tetrakis(4-carboxyphenyl)porphine for treating cancers of the lung. patents.ibm.com
Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung. patents.ibm.com
ADOT is positioned to benefit from this because of ADOT's 27% ownership interest in Biomoda and ADOT is also capable of producing the equipment used in the commercial application of Biomoda's patented medical technology.
- - - - - - - - - - - - - - - - - - - -
Overview of The Technology and Its Progress -
The Biomoda process is the result of many years of study and research by some of the most highly respected cytopathologists in the world. Including, in fact, the world's leading cytopathologist, Dr Geno Saccomanno.
(Please see Dr Saccomanno's credentials later in this report)
The technology utilizes an exclusively licensed synthetic TCPP (a photoreactive porphyrin compound) that is rapidly absorbed by cancer cells, particularly lung cancer cells. One of the important characteristics of TCPP is that it fluoresces red when exposed to ultraviolet light. Current methods of cytological detection depend on human visualization and subjective interpretation or pattern recognition to locate abnormal cells.
This technology was originally developed through research done by the US Government at Los Alamos & Sandia Laboratories Medical Isotopes Program and St Mary's Hospital & Medical Center in Colorado. It involved such well known researchers as Dr. Jim Mulshine of the National Cancer Institute and the late Dr. John Frost of Johns Hopkins
University in addition to Dr Saccomanno.
Biomoda originally tested 3,500 samples at St Mary's Hospital & Medical Center and at Johns Hopkins University. The findings of those tests were considered extremely favorable, but more scientific studies were required to establish the efficacy of the early cancer detection process.
So a 15 patient "single blind study" done between St. Mary's Hospital & Medical Center and Los Alamos National Labs was conducted. Five (5) of the 15 were "control" samples (non-cancerous) and ten (10) were cancerous. However, when the samples were tested using the Biomoda process, only 4 were found non-cancerous and 11 were found cancerous. Indeed, the test found cancer in one of the samples that had not been detected previously. And the diagnosis was correct.
Biomoda is currently doing a 60 patient (2 samples each) "double blind study" at a cytopathology lab in Arizona. Those 120 slides will be the subject of another "blind study" at the University of Pennsylvania Medical School for independent confirmation by a group of Board Certified Pathologists. Those results are expected to be presented for review to various organizations including the American Cancer Society, the American Lung Assn, and the American Pathology Assn. Biomoda expects to have this completed by around September 1, 1998.
An additional "double blind study" using up to 300 patient samples is expected to be conducted starting in September simply to provide further statistical data to support the remarkable capabilities of this unique process. The larger study is NOT needed in order to market the "early detection" test.
The patents for this technology have been issued in the USA, Australia, and Russia. Patent applications are pending in 17 other countries.
Wide scale application of Biomoda's early detection technology requires standardization and automation of readings. The patented technology ADOT uses can provide the image analysis automation necessary for large-scale screening in cytopathology labs across the
country and around the world.
Click Here to see a demonstration of how this technology works:
biomoda.com
Biomoda technology covers Early Detection and Treatment separately.
Early Detection of Cancer... The cytology reagents are regulated by FDA as chemical solution stains under 21CFR864.1850. Devices in this category are both Class 1 devices and explicitly exempted by statute from 510k premarket notification procedures.
Biomoda adapts its reagents and testing methodologies to diagnostic devices already approved by the FDA and in the marketplace. This exemption applies to the early detection process only, so it is possible for this process to be marketed very soon.
Treatment... The treatment process will require FDA approval so it will have to follow the standard course for that approval. Biomoda has already been approached by several major pharmaceutical companies (including Schering AG/Berlex Laboratories and others) interested in Biomoda's process. One of these prospective major partners will likely play a large role in the application of the treatment technology.
The early detection cancer test can be expected to improve 5-year survival rates from 13% up to 46%. With the advent of Biomoda's new lung cancer treatment, this diagnostic/treatment program can be expected to increase these survival rates even further.
- - - - - - - - - - - - - - - - - - - -
The Numbers -
The early cancer detection test can be as easy as brushing your teeth.
It can detect lung cancer 6 years earlier than other tests currently used.
Other types of cancers can also be detected using this technology.
Annual screening can benefit 77 million Americans over age 45 who are at risk.
Sample can be done at home in minutes and mailed in (or delivered) for screening.
The test would cost about $10 at the store and about $20 for screening fees.
Thousands of Diagnostic Centers across the country and around the world could process the samples quickly and easily using Biomoda's specifically designed technology.
Multiple samples would be processed by computerized photo-imaging and the "positive" cases would then be reviewed by a pathologist for the appropriate next steps for the patient.
For consumers, the test is easy, simple and the results can prove life-saving.
People at risk (or just curious about their health) can get results quickly and efficiently.
The test could be used by insurance companies to determine risks among applicants.
Biomoda is also working with companies to provide this technology in Europe, China and Latin America, as well as in the USA.
In China, lung cancer has become a national epidemic where over 900,000 people a year die from lung cancer. China has over 300 million smokers and the Chinese Government recognizes the severity of the problem.
For the past 2 years, Biomoda has been working with the Shanghai Center of New Drug Development (an entity of the Chinese Government and the city of Shanghai), to develop a program utilizing this early detection and treatment technology. The Shanghai Center has signed a Letter of Intent with Biomoda and wants Biomoda to deliver a "turn-key"operation that they can use to fight this problem. Biomoda is now working on a plan to address this opportunity.
Biomoda hopes to have its first "sale" of Early Cancer Detection Kits by the end of September and begin receiving revenues during the 4th Quarter of this year.
For Lung Cancer Screening - At $10 per test, the potential annual market just for all smokers over age 45 in the USA alone, is $770 Million!
For all people in the USA over the age of 40, it's estimated at $1.4 Billion !!
For Lung Cancer Treatment - Biomoda estimates the present market for lung cancer therapies is about $450 Million and Biomoda expects to retain a significant share of that market through possible joint ventures with a major pharmaceutical partner.
PAP smear tests could also be replaced using this technology. PAP smear tests have long been considered inaccurate and create many problems from false "positive" and false "negative" readings. If PAP smear tests were applying for FDA approval today, they would not be approved. Biomoda's technology can be far more effective. This market is considered to be extremely large.
Biomoda expects to begin aggressive marketing in the 4th Quarter of 1998 (per CEO of Biomoda). This goal might very well involve Schering AG/Berlex Laboratories or another major pharmaceutical company. However, Biomoda is also preparing a plan to market the "early cancer detection" tests independently, if necessary.
********************************************************
SUMMARY:
So ADOT can benefit from BIOMODA's program in 2 ways as follows:
1. ADOT has the capability to design, manufacture and distribute the scanning test devices used for the lung cancer tests.
2. ADOT owns 27% of BIOMODA, Inc. Income from BIOMODA will directly benefit ADOT and subsequently ADOT shareholders.
*******************************************************
CREDIBILITY:
Biomoda has been contacted by BERLEX LABORATORIES on behalf of its parent company, SCHERING AG. Schering AG is a German-based pharmaceutical and medical technology company headquartered in Berlin. Schering AG, with over $3.8 Billion ($U.S.) in annual revenues and offices worldwide, is a recognized leader in biotechnology research and the use of contrast media in the diagnosis and treatment of a
variety of diseases. Here are the web sites for Schering AG and Berlex Laboratories.
schering.de
betaseron.com
Biomoda Inc also happens to be featured as one of the main Lung Cancer Information Links at the Roy Castle Lung Cancer Foundation in Great Britain. This foundation has built the world's first lung cancer research center in Liverpool, UK.
roycastle.org (click on "links")
SCIENTIFIC ADVISORY BOARD Includes Noted Leader in Lung Cancer Research:
Geno Saccomanno, M.D., Ph.D. of St. Mary's Hospital and Medical Center in Colorado.Dr Saccomanno is considered "the world's best pulmonary cyto-pathologist."
emphysemafoundation.org
Dr Saccomanno is one of the most highly respected lung cancer researchers in the world. He has been actively involved in lung cancer research for over 40 years and is most noted for his lung cancer research involving uranium miners throughout Colorado. He works
closely with the US Dept of Justice and the US Dept of Energy.
Dr. Saccomanno is associated with the St. Mary's Hospital School of Cytotechnology and the St. Mary's Cancer Research Institute, has been involved in lung cancer research since 1957. He authored the textbook, Diagnostic Pulmonary Cytology, and has been the recipient of many scientific honors for his pioneering work in lung cancer research and
early detection.
Medical cytopathology awards given in countless countries around the world are named in honor of Dr Saccomanno for his work in this area.
------------
Here are a few more sites that reflect his work.
aacr.org
aacr.org
niehs.nih.gov
columbia.net
uchsc.edu
eml.doe.gov
ehpnet1.niehs.nih.gov
biomoda.com
junkscience.com
seas.gwu.edu
med.nyu.edu
In addition to Dr Saccomanno, Biomoda's other noted researchers include:
Dr. L. Edward Ellinwood, a distinguished pharmacologist and physician associated with St.Mary's Hospital and Los Alamos National Laboratory, has been involved with research on the early detection and treatment of lung cancer in uranium miners. He has published extensively in this field as well as on the effects of radiation on body tissue and organs. He is the one of the contributors to the patents which the Company has licensed.
Dr. Buck Rhodes, has over thirty years of expertise in the field of radiopharmaceutical research. He has published or co-published more than 160 scientific papers, seven textbooks, eight audio visual programs and has been issued 12 medical product-related patents with 12 patents pending. Most recently, Dr. Rhodes served as president of
RhoMed Incorporated. He is an honorary diplomat to the the American Board of Science in Nuclear Medicine and holds a PhD in radiological science from the Johns Hopkins University.
Here are the bios on the Scientific Advisory Board for Biomoda:
biomoda.com
Biomoda CEO and President -
Mr. Ari Ma'ayan, age 54, has been a Director of the Company since 1990. Mr. Ma'ayan is a seasoned biotechnology executive with broad experience in strategic planning, product and process development, manufacturing, quality control, and regulatory compliance issues. He will be directly involved in technology and product transfer.
He has served as Vice President for RhoMed, Inc., ChemBioMed, Inc., and American BioDesign, Inc. He held senior staff positions at Biogen, Inc. and Genzyme Corp. He is a Clinical Assistant Professor of Pharmacy at the University of New Mexico. Mr. Ma'ayan's academic experience includes research and development assignments with Ben Gurion University, University of Texas, and the Hebrew University of Jerusalem School of Medicine. He has been the recipient of honors from the Canadian National Research Council, American Cancer Society, and a grant recipient of the National Institutes of Health and the Canadian National Research Council. Mr. Ma'ayan holds a BSC from the Hebrew University of Jerusalem.
*******************************************************
OTHER CONSIDERATIONS:
$1 million financing in 8% convertible subordinated debentures with an 18 month restricted term was completed in October, 1997. The restriction does not expire until April, 1999.
ADOT apparently issued an equity placement earlier this year that increased the total shares outstanding to about 12 million. It appears that at least part of that funding was used to increase ADOT's ownership of Biomoda, Inc.
ADOT is also continuing negotiations with the previously announced space and information technologies company. The space and information technologies company is estimated to generate minimum revenues of $8 million a year over the next five years with $10 million in backlog orders. The firm services a broad customer base including the U.S. Air Force, Boeing, Lockheed Martin, Honeywell, Department of Defense,
Department of Energy, Federal Aviation Administration, Sandia and Los Alamos National Laboratories, and the Veterans Administration.
ADOT also announced recently that preliminary discussions have begun with Literal Corp for the acquisition of certain patents and a possible equity interest in Literal. Literal Corp holds numerous patents relating directly and indirectly to data transmission and
compression for optically sensed and transmitted information.
Biomoda, Inc is listed on numerous sites referencing providers of Diagnostic & Pharmaceutical products...
ispex.ca
medmarket.com
galaxy.einet.net:8000/galaxy/Business-and-Commerce/General-Products-and-Services/Health-and-Medicine/Pharmaceuticals.html
nbif.org
ms.yahoo.com
TALK FORUMS:
Silicon Investor - Subject 16128
Raging Bull - ragingbull.com
TODAY'S QUOTE:
(Type "ADOT" in the "Real Time" box)
freerealtime.com:8001/
or 15-minute delayed with news:
quote.yahoo.com
CHART:
tscn.com
HISTORICAL PRICING: (Type the "ADOT" in the Symbol box)
tradepbs.com
INSIDER BUYING / SELLING REPORTS:
insidertrader.com
********************************************************
WHY I LIKE THIS COMPANY:
1. Enormous Profit potential from BIOMODA.
2. Excellent Profit potential from Flat Panel Displays
3. Small Float
4. Biomoda's early cancer detection and treatment is "Breakthrough Technology!"
5. Cancer research & treatment claims are verifiable!
6. Ownership in Biomoda and the acquisitions under consideration appear to enhance ADOT's posture in it's primary market.
7. Biomoda could be acquired by a major pharmaceutical firm very soon.
8. Revenue streams should begin shortly from both ADOT and Biomoda.
9. ADOT already provides Audited Financial information on their web site.
10. Biomoda seems very open in providing information about their technology.
********************************************************
PLEASE NOTE:
I am NOT associated with this company in any way. I am an individual investor with my own opinions. I don't give advice. Questions should be directed to the appropriate source, many of which are listed above. Everyone is urged to do their own research before investing in anything.
Best wishes,
Brad |
